A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT06635057

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06635057
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Saudi Arabia, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06635057. Allocation not applicable; no masking; primary purpose treatment. Start 2024-10-11 (actual); primary completion 2026-04-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
Acronym
T-RAM
Intervention (Drug)
Tirzepatide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06635057
Content hash
cdfbbe4e4fad407660e919a07698d5b15f0ac29ec555b906420fbf83946d3abf